Meet the CEO of Europe’s Leading Microbiome Biotech

03/02/2016 - 5 minutes

We met Pierre Belichard, the CEO of Enterome, last week to discuss the increasingly famous trend in the Human Microbiome and how this is impacting therapeutics in Crohn’s disease, the understanding of Medical Microbiomics and investment in this field of Biotech. 

Enterome, established in 2012, is a French biotech that is hot at the moment, having already raised €17.5M from a syndicate that included Seventure and two strategic investors, Shire and INRA Transfert. Now Enterome is looking to further develop their Microbiome platform for diseases such as Crohn’s Disease – a severe and debilitating form of Irritable Bowel Disease (IBD).

Pierre Belichard was the founder and COO of Fovea and has been instrumental in building up the product portfolio that became the Ophthalmology division of Sanofi. Pierre has also served as the VP of UroGene, sold to Pierre Fabre in 2004, and Head of European commercial operations at Ethypharm.


So, there are at least 10 Microbiome companies in the World.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member